BiotechTube

HSK31858 + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma

Trial Timeline

Oct 22, 2024 → Sep 20, 2026

NCT ID
NCT06637254

About HSK31858 + Placebo

HSK31858 + Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Bronchial Asthma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06637254. Target conditions include Bronchial Asthma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT06820749Phase 2Recruiting
NCT06637254Phase 2Recruiting
NCT05601778Phase 2Completed

Competing Products

20 competing products in Bronchial Asthma

See all competitors
ProductCompanyStageHype Score
TacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 2
52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
77
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
77
Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3
77
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
77
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerGlenmark PharmaceuticalsPhase 3
77
Symbicort Turbuhaler + Symbicort pMDI + Pulmicort TurbuhalerAstraZenecaPhase 3
77
RoflumilastAstraZenecaPhase 3
77
RoflumilastAstraZenecaPhase 2/3
65
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatmentAstraZenecaPhase 3
77
CiclesonideAstraZenecaPhase 3
77
Montelukast plus prednisolone + PrednisoloneMerckPhase 2
52
MontelukastMerckApproved
85
Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
85
inhaled corticosteroid therapyNovartisPhase 1/2
41
PF-00610355 + PF - 00610355 + PF - 00610355PfizerPhase 2
51
NivolumabBristol Myers SquibbPhase 2
51
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
49

Other Products from Haisco Pharmaceutical Group

Crisugabalin + PlaceboApproved
82
Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDApproved
82
Cyclopofol + PropofolApproved
82
Ciprofol + PropofolApproved
82
CipepofolApproved
82